TransMedics Group, Inc. (NASDAQ:TMDX) Receives Consensus Rating of “Moderate Buy” from Analysts

TransMedics Group, Inc. (NASDAQ:TMDX) has been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $122.70.

Several research analysts recently commented on the stock. Piper Sandler reduced their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. TD Cowen reduced their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Oppenheimer reissued an “outperform” rating and set a $125.00 price target on shares of TransMedics Group in a research report on Tuesday, December 3rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Wednesday, December 11th.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the sale, the insider now directly owns 20,843 shares in the company, valued at $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the sale, the director now owns 732 shares of the company’s stock, valued at $61,158.60. This trade represents a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

Several hedge funds have recently added to or reduced their stakes in TMDX. Driehaus Capital Management LLC lifted its holdings in TransMedics Group by 15.8% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after purchasing an additional 202,867 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of TransMedics Group by 260.1% during the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after buying an additional 146,115 shares in the last quarter. Hood River Capital Management LLC acquired a new stake in TransMedics Group in the 2nd quarter worth about $18,854,000. Canada Pension Plan Investment Board acquired a new stake in TransMedics Group in the 2nd quarter worth about $16,086,000. Finally, Public Sector Pension Investment Board acquired a new stake in TransMedics Group in the 3rd quarter worth about $11,079,000. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $60.82 on Friday. The firm has a market cap of $2.04 billion, a PE ratio of 64.70 and a beta of 2.12. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. TransMedics Group has a 1-year low of $55.00 and a 1-year high of $177.37. The company has a fifty day moving average price of $69.04 and a 200 day moving average price of $115.58.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.17). The firm had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm’s quarterly revenue was up 63.7% on a year-over-year basis. During the same period in the prior year, the company earned ($0.12) earnings per share. Research analysts predict that TransMedics Group will post 1 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.